Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP trimmed its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 41.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,684 shares of the company’s stock after selling 8,944 shares during the period. GSA Capital Partners LLP’s holdings in Tarsus Pharmaceuticals were worth $754,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in TARS. Osaic Holdings Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after purchasing an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after purchasing an additional 2,782 shares in the last quarter. West Wealth Group LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $202,000. Valeo Financial Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $209,000. Finally, Allianz Asset Management GmbH purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at approximately $227,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This trade represents a 15.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on TARS. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research raised Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Barclays initiated coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Finally, Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $82.29.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $66.61 on Friday. The company has a market cap of $2.83 billion, a P/E ratio of -32.98, a P/E/G ratio of 0.96 and a beta of 0.57. The business has a fifty day simple moving average of $72.54 and a 200-day simple moving average of $67.82. Tarsus Pharmaceuticals, Inc. has a 52 week low of $38.51 and a 52 week high of $85.25. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.